Skip to main content
Clinical Trials/NCT04071132
NCT04071132
Unknown
Not Applicable

Using Adhesive Biosensor Patches to Characterize the Biochemical Phenotype in Individuals Diagnosed With PTSD

Nadav Goldental0 sites50 target enrollmentAugust 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post Traumatic Stress Disorder
Sponsor
Nadav Goldental
Enrollment
50
Primary Endpoint
Changes in c-reactive protein (CRP)
Last Updated
6 years ago

Overview

Brief Summary

A psychiatric diagnosis of post-traumatic stress disorder (PTSD) is currently based mainly on non-quantitative elements, such as interviews and subjective impressions. PTSD has physiological manifestations, some of which are likely reflected in the levels and ratios of certain stress-related proteins in the interstitial fluid and plasma. Discernable patterns of such stress-related proteins may constitute a biochemical phenotype characteristic of PTSD, which may serve as a biomarker and support diagnostic decisions, as well as personalized treatment plans.

The current study is a non-interventional observational study aimed at examining the possibility of basing a psychiatric diagnosis by measuring changes in the biochemical phenotype of participants with PTSD.

Registry
clinicaltrials.gov
Start Date
August 2019
End Date
September 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Nadav Goldental

Principal investigator

The Chaim Sheba Medical Center

Eligibility Criteria

Inclusion Criteria

  • PTSD diagnosis (excluding controls)
  • Proper ability to give informed consent

Exclusion Criteria

  • Active psychotic or suicidal symptoms
  • Active/terminal oncological condition
  • Dialysis patients
  • Pregnancy

Outcomes

Primary Outcomes

Changes in c-reactive protein (CRP)

Time Frame: 3 months

Changes in c-reactive protein (CRP) levels as measured by the adhesive biosensor patches

Changes in Interleukin 6 (IL-6) levels

Time Frame: 3 months

Changes in Interleukin 6 (IL-6) levels as measured by the adhesive biosensor patches

Changes in cortisol levels

Time Frame: 3 months

Changes in cortisol levels as measured by the adhesive biosensor patches

Changes in N-terminal pro b-type Natriuretic Peptide (NT-proBNP) levels

Time Frame: 3 months

Changes in N-terminal pro b-type Natriuretic Peptide (NT-proBNP) levels as measured by the adhesive biosensor patches

Changes in glucose levels

Time Frame: 3 months

Changes in glucose levels as measured by the adhesive biosensor patches

Changes in 8-Oxo-2'-deoxyguanosine (8-oxo-dg) levels

Time Frame: 3 months

Changes in 8-Oxo-2'-deoxyguanosine (8-oxo-dg) levels as measured by the adhesive biosensor patches

Changes in volatile organic compounds (VOCs) levels

Time Frame: 3 months

Changes in volatile organic compounds (VOCs) concentrations (hexanone, acetic acid, heptane, hexanal, 3-heptanone, hexanoic acid, heptanal and nonanal) as measured by the adhesive biosensor patches

Correlations between biochemical changes and PTSD clinical symptoms

Time Frame: 3 months

Correlations between biochemical changes and questionnaire data relating to PTSD clinical symptoms (CGI, CAPS, PHQ, PCL-5, PC-PTSD-5, LEC-5 and BARS).

Similar Trials